Title | Type | ![]() |
H index | Total Docs. (2016) | Total Docs. (3years) | Total Refs. (2016) | Total Cites (3years) | Citable Docs. (3years) | Cites / Doc. (2years) | Ref. / Doc. (2016) | %Female (2016) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Diabetes, Metabolic Syndrome and Obesity![]() | journal | 1.586 Q1 | 64 | 45 | 168 | 2511 | 744 | 165 | 4.42 | 55.80 | 38.10 | ![]() |
2 | Infection and Drug Resistance![]() | journal | 1.551 Q1 | 65 | 33 | 101 | 1683 | 449 | 101 | 4.89 | 51.00 | 36.27 | ![]() |
3 | Pharmacogenomics and Personalized Medicine![]() | journal | 1.208 Q1 | 37 | 15 | 67 | 912 | 289 | 67 | 4.76 | 60.80 | 40.48 | ![]() |
4 | International Journal of Nanomedicine![]() | journal | 1.174 Q1 | 179 | 487 | 1501 | 23728 | 7347 | 1472 | 4.56 | 48.72 | 43.58 | ![]() |
5 | Nanotechnology, Science and Applications![]() | journal | 1.048 Q1 | 35 | 4 | 12 | 548 | 106 | 12 | 8.83 | 137.00 | 27.78 | ![]() |
6 | Drug Design, Development and Therapy![]() | journal | 0.993 Q1 | 94 | 363 | 908 | 15594 | 2911 | 893 | 3.04 | 42.96 | 37.71 | ![]() |
7 | Core Evidence (discontinued)![]() | journal | 0.965 Q2 | 29 | 5 | 28 | 371 | 116 | 27 | 4.24 | 74.20 | 43.75 | ![]() |
8 | Patient Preference and Adherence![]() | journal | 0.790 Q1 | 67 | 254 | 477 | 9951 | 1091 | 466 | 2.04 | 39.18 | 48.33 | ![]() |
9 | Biomarker Insights![]() | journal | 0.699 Q2 | 40 | 29 | 97 | 1744 | 195 | 95 | 1.79 | 60.14 | 44.79 | ![]() |
10 | Drug, Healthcare and Patient Safety![]() | journal | 0.531 Q3 | 30 | 13 | 66 | 469 | 112 | 60 | 1.95 | 36.08 | 40.48 | ![]() |
11 | Fluoride - Quarterly Reports![]() | journal | 0.332 Q4 | 51 | 55 | 108 | 1702 | 184 | 98 | 1.84 | 30.95 | 40.80 | ![]() |
12 | Open Access Journal of Clinical Trials![]() | journal | 0.305 Q2 | 15 | 6 | 27 | 162 | 24 | 25 | 0.54 | 27.00 | 27.27 | ![]() |
Follow us on @ScimagoJR
Scimago Lab, Copyright 2007-2024. Data Source: Scopus®